Alkermes (ALKS) Proxy filing summary

Executive summary

• Annual General Meeting scheduled for May 20, 2026, to address director elections, executive compensation, auditor ratification, equity plan amendments, and share issuance authorities.

• 2025 business priorities focused on commercial growth, pipeline advancement, and profitability, with revenue exceeding $1.48 billion and net income of $242 million.

• Acquisition of Avadel Pharmaceuticals completed in February 2026, expanding the sleep medicine portfolio.

Voting matters and shareholder proposals

• Election of nine directors for one-year terms, all recommended by the Board.

• Advisory vote on executive compensation (say-on-pay), with Board recommending approval.

• Ratification of PwC as independent auditor and authorization for the Audit and Risk Committee to set remuneration.

• Approval sought for amendments to the 2018 Stock Option and Incentive Plan, increasing share reserve by 5.9 million shares.

• Renewal of Board authority to allot and issue shares and to disapply statutory pre-emption rights under Irish law.

Board of directors and corporate governance

• Board comprises nine members, eight of whom are independent; four are diverse by gender or ethnicity.

• Recent enhancements include declassification, refreshment of membership, and strengthened disclosure and assessment processes.

• Lead Independent Director and committee chairs are independent; Board regularly reviews leadership structure.

• Active shareholder engagement and responsiveness to feedback, including changes to governance and compensation practices.